Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant for Acute Treatment of TMD
NCT05262517Phase 3Terminated
- Sponsor
- Pfizer
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in temporomandibular disorders (TMD) comparing Rimegepant 75mg with Placebo (2 arms). Primary endpoints: Sum of Pain Intensity Difference From Baseline to 2-Hours Post-dose and Sum of Pain Intensity Difference From Baseline to 24-Hours Post-dose. Started May 2022; status: terminated.
02
Drugs
rimegepant
03
Conditions
temporomandibular disorders (TMD)
Beyond the preview
Go deeper on NCT05262517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05262517.